{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T10:46:17Z","timestamp":1758969977402,"version":"3.37.3"},"reference-count":43,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T00:00:00Z","timestamp":1594425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Takeda Pharma Vertrieb GmbH&Co. KG"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Health Econ"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n<jats:title>Background<\/jats:title>\n<jats:p>In Germany, several triplet therapies for treating relapsed or refractory multiple myeloma (rrMM) patients have recently been approved. While most of them are administered intravenously, ixazomib-based combination is the only orally bioavailable regimen.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Objective<\/jats:title>\n<jats:p>To conduct a 1-year and 3-year budget impact analysis (BIA) of different novel triplets to treat patients with rrMM in second or subsequent therapy lines accounting for costs covered by German statutory health insurance (SHI).<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Methods<\/jats:title>\n<jats:p>A 3-state partitioned survival model (PSM) was developed to evaluate the budget impact of the following regimens: carfilzomib plus lenalidomide plus dexamethasone (KRd), elotuzumab plus lenalidomide plus dexamethasone (ERd), daratumumab plus lenalidomide plus dexamethasone (DRd), and ixazomib plus lenalidomide plus dexamethasone (IRd). The analysis included direct medical costs such as drug acquisition, comedication and preparation for parenteral solutions, drug administration and other 1-time costs, adverse event management costs and direct non-medical costs, such as transportation costs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Results<\/jats:title>\n<jats:p>Based on current drug market shares in German healthcare market, the estimated costs after 1\u00a0year of treatment was \u20ac551 million (KRd), \u20ac163 million (ERd), \u20ac584 million (DRd), and \u20ac95 million (IRd). The total budget impact of \u20ac1393 million is mainly driven by drug acquisition and subsequent therapy costs.<\/jats:p>\n<\/jats:sec><jats:sec>\n<jats:title>Conclusion<\/jats:title>\n<jats:p>Among the regimens of interest, the oral-based therapy regimens offered cost advantages over intravenous-based therapy regimens. The higher overall costs of intravenous therapy regimens were attributed primarily to higher drug acquisition\u00a0costs.<\/jats:p>\n<\/jats:sec>","DOI":"10.1007\/s10198-020-01219-3","type":"journal-article","created":{"date-parts":[[2020,7,11]],"date-time":"2020-07-11T06:02:33Z","timestamp":1594447353000},"page":"1351-1361","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Budget impact analysis of the use of oral and intravenous therapy regimens for the treatment of relapsed or refractory multiple myeloma in Germany"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7351-2910","authenticated-orcid":false,"given":"Edin","family":"Basic","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mathias","family":"Kappel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arpit","family":"Misra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leopold","family":"Sellner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Boris A.","family":"Ratsch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dennis A.","family":"Ostwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,7,11]]},"reference":[{"issue":"11","key":"1219_CR1","doi-asserted-by":"publisher","first-page":"1046","DOI":"10.1056\/NEJMra1011442","volume":"364","author":"A Palumbo","year":"2011","unstructured":"Palumbo, A., Anderson, K.: Multiple myeloma. N. Engl. J. Med. 364(11), 1046\u20131060 (2011)","journal-title":"N. Engl. J. Med."},{"key":"1219_CR2","unstructured":"Deutsche Gesellschaft f\u00fcr H\u00e4matologie und Onkologie e.V. Multiples Myelom. onkopedia leitlinien [Internet] (2018). https:\/\/www.onkopedia.com\/de\/onkopedia\/guidelines\/multiplesmyelom\/@@view\/html\/index.html. Accessed 21 Apr 2019"},{"issue":"2","key":"1219_CR3","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart, A.K., Rajkumar, S.V., Dimopoulos, M.A., et al.: Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N. Engl. J. Med. 372(2), 142\u2013152 (2015)","journal-title":"N. Engl. J. Med."},{"issue":"7","key":"1219_CR4","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial, S., Dimopoulos, M., Palumbo, A., et al.: Elotuzumab therapy for relapsed or refractory multiple myeloma. N. Engl. J. Med. 373(7), 621\u2013631 (2015)","journal-title":"N. Engl. J. Med."},{"issue":"17","key":"1219_CR5","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau, P., Masszi, T., Grzasko, N., et al.: Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 374(17), 1621\u20131634 (2016)","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"1219_CR6","doi-asserted-by":"publisher","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M.A., Oriol, A., Nahi, H., et al.: Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(14), 1319\u20131331 (2016)","journal-title":"N. Engl. J. Med."},{"key":"1219_CR7","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1016\/j.ctrv.2010.04.005","volume":"36","author":"GL Banna","year":"2010","unstructured":"Banna, G.L., Collova, E., Gebbia, V., et al.: Anticancer oral therapy: emerging related issues. Cancer Treat. Rev. 36, 595\u2013605 (2010)","journal-title":"Cancer Treat. Rev."},{"key":"1219_CR8","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1038\/sj.bjc.6600591","volume":"87","author":"VJ O\u2019Neill","year":"2002","unstructured":"O\u2019Neill, V.J., Twelves, C.J.: Oral cancer treatment: developments in chemotherapy and beyond. Br. J. Cancer 87, 933\u2013937 (2002)","journal-title":"Br. J. Cancer"},{"issue":"4","key":"1219_CR9","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1016\/j.mayocp.2017.01.003","volume":"92","author":"D Dingli","year":"2017","unstructured":"Dingli, D., Ailawadhi, S., Bergsagel, P.L., et al.: Therapy for relapsed multiple myeloma: guidelines from the mayo stratification for myeloma and risk-adapted therapy. Mayo Clin. Proc. 92(4), 578\u2013598 (2017)","journal-title":"Mayo Clin. Proc."},{"key":"1219_CR10","unstructured":"Robert Koch-Institut und Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (RKI). Krebs in Deutschland 2013\/2014 (2017). https:\/\/www.krebsdaten.de\/Krebs\/DE\/Content\/Publikationen\/Krebs_in_Deutschland\/kid_2017\/krebs_in_deutschland_2017.pdf"},{"issue":"5","key":"1219_CR11","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/leu.2013.293","volume":"28","author":"H Ludwig","year":"2014","unstructured":"Ludwig, H., Miguel, J.S., Dimopoulos, M.A., et al.: International Myeloma Working Group recommendations for global myeloma care. Leukemia 28(5), 981\u2013992 (2014)","journal-title":"Leukemia"},{"issue":"suppl_4","key":"1219_CR12","doi-asserted-by":"publisher","first-page":"iv52","DOI":"10.1093\/annonc\/mdx096","volume":"28","author":"P Moreau","year":"2017","unstructured":"Moreau, P., San Miguel, J., Sonneveld, P., et al.: Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 28(suppl_4), iv52\u2013iv61 (2017)","journal-title":"Ann. Oncol."},{"key":"1219_CR13","unstructured":"O.I.s. Oncology Information Service. TherapieMonitor Multiples Myelom. (2019)"},{"issue":"6","key":"1219_CR14","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1007\/s00277-017-2991-0","volume":"96","author":"M Merz","year":"2017","unstructured":"Merz, M., Kellermann, L., Poenisch, W., et al.: Diagnosis and treatment of multiple myeloma in Germany: analysis of a nationwide multi-institutional survey. Ann. Hematol. 96(6), 987\u2013993 (2017)","journal-title":"Ann. Hematol."},{"issue":"8","key":"1219_CR15","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo, A., Chanan-Khan, A., Weisel, K., et al.: Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N. Engl. J. Med. 375(8), 754\u2013766 (2016)","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"1219_CR16","doi-asserted-by":"publisher","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","volume":"15","author":"JF San-Miguel","year":"2014","unstructured":"San-Miguel, J.F., Hungria, V.T., Yoon, S.S., et al.: Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial. Lancet Oncol. 15(11), 1195\u20131206 (2014)","journal-title":"Lancet Oncol."},{"issue":"11","key":"1219_CR17","doi-asserted-by":"publisher","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"J San Miguel","year":"2013","unstructured":"San Miguel, J., Weisel, K., Moreau, P., et al.: Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, openlabel, phase 3 trial. Lancet Oncol. 14(11), 1055\u20131066 (2013)","journal-title":"Lancet Oncol."},{"key":"1219_CR18","unstructured":"EMA European Medicine Agency. Darzalex: EPAR\u2014Public assessment report (2016). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/darzalex-epar-public-assessment-report_en.pdf. Accessed 21 Apr 2019"},{"key":"1219_CR19","unstructured":"EMA European Medicine Agency. Empliciti: EPAR\u2014Public assessment report (2016). https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/empliciti-epar-public-assessment-report_en.pdf. Accessed 21 Apr 2019"},{"key":"1219_CR20","unstructured":"EMA European Medicine Agency. Ninlaro: EPAR\u2014Public assessment report (2016). https:\/\/www.ema.europa.eu\/documents\/assessment-report\/ninlaro-epar-public-assessment-report_en.pdf. Accessed 21 Apr 2019."},{"key":"1219_CR21","unstructured":"Rohatgi A. WebPlotDigitizer Version 3.9. https:\/\/arohatgi.info\/WebPlotDigitizer. Accessed 5 Dec 2016"},{"issue":"8","key":"1219_CR22","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1186\/1745-6215-8-16","volume":"7","author":"JF Tierney","year":"2007","unstructured":"Tierney, J.F., Stewart, L.A., Ghersi, D., et al.: Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 7(8), 16 (2007)","journal-title":"Trials"},{"issue":"4","key":"1219_CR23","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1177\/1536867X1801700402","volume":"17","author":"Y Wei","year":"2017","unstructured":"Wei, Y., Royston, P.: Reconstructing time-to-event data from published Kaplan\u2013Meier curves. Stata J. 17(4), 786\u2013802 (2017)","journal-title":"Stata J."},{"key":"1219_CR24","unstructured":"European Medicines Agency. Empliciti: EPAR\u2014Product Information (2019). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/empliciti-epar-product-information_de.pdf"},{"key":"1219_CR25","unstructured":"European Medicines Agency. Kyprolis: EPAR\u2014Product Information (2019). https:\/\/ec.europa.eu\/health\/documents\/community-register\/2016\/20160629135251\/anx_135251_de.pdf"},{"key":"1219_CR26","unstructured":"European Medicines Agency. Darzalex: EPAR\u2014Product Information (2019). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/darzalex-epar-product-information_de.pdf"},{"key":"1219_CR27","unstructured":"European Medicines Agency. Ninlaro: EPAR\u2014Product Information (2019). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/ninlaro-epar-product-information_de.pdf"},{"key":"1219_CR28","unstructured":"European Medicines Agency. Imnovid: EPAR\u2014Product Information (2019). https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/imnovid-epar-product-information_en.pdf"},{"key":"1219_CR29","unstructured":"European Medicines Agency. Farydak: EPAR\u2014Product Information (2019). https:\/\/ec.europa.eu\/health\/documents\/community-register\/2015\/20150828132600\/anx_132600_de.pdf"},{"key":"1219_CR30","unstructured":"Lauer Taxe. Kundencenter\u2014LAUER-FISCHER GmbH, F\u00fcrth. https:\/\/www.lauer-fischer.de\/LF\/Seiten\/Verwaltung\/Kundencenter\/1.aspx. Accessed 21 Apr 2019"},{"key":"1219_CR31","unstructured":"Bundesversicherungsamt [German Federal Insurance Authority] (2019). https:\/\/www.bundesversicherungsamt.de\/risikostrukturausgleich\/festlegungen.html"},{"key":"1219_CR32","doi-asserted-by":"publisher","first-page":"2387","DOI":"10.2147\/PPA.S183187","volume":"12","author":"T Wilke","year":"2018","unstructured":"Wilke, T., Mueller, S., Bauer, S., et al.: Treatment of relapsed refractory multiple myeloma: which new PI-based combination treatments do patients prefer? Patient Prefer. Adher. 12, 2387\u20132396 (2018)","journal-title":"Patient Prefer. Adher."},{"key":"1219_CR33","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1111\/j.1524-4733.2007.00187.x","volume":"10","author":"JA Mauskopf","year":"2007","unstructured":"Mauskopf, J.A., Sullivan, S.D., Annemans, L., et al.: Principles of good practice for budget impact analysis: report of the ISPOR task force on good research practices\u2014budget impact analysis. Value Health 10, 336\u2013347 (2007)","journal-title":"Value Health"},{"issue":"11","key":"1219_CR34","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.1080\/10428194.2018.1437269","volume":"59","author":"C Shah","year":"2018","unstructured":"Shah, C., Bishnoi, R., Jain, A., et al.: Cardiotoxicity associated with carfilzomib: systematic review and meta-analysis. Leuk Lymphoma 59(11), 2557\u20132569 (2018)","journal-title":"Leuk Lymphoma"},{"key":"1219_CR35","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1007\/s00520-015-2644-6","volume":"23","author":"R Baz","year":"2015","unstructured":"Baz, R., Lin, H.M., Hui, A.M., et al.: Development of a conceptual model to illustrate the impact of multiple myeloma and its treatment on health-related quality of life. Support Care Cancer 23, 2789\u20132797 (2015)","journal-title":"Support Care Cancer"},{"key":"1219_CR36","doi-asserted-by":"publisher","first-page":"e408","DOI":"10.1016\/S2352-3026(15)00151-9","volume":"2","author":"SF Huntington","year":"2015","unstructured":"Huntington, S.F., Weiss, B.M., Vogl, D.T., et al.: Financial toxicity in insured patients with multiple myeloma: a cross sectional pilot study. Lancet Haematol. 2, e408\u2013e416 (2015)","journal-title":"Lancet Haematol."},{"key":"1219_CR37","unstructured":"Barmer Arzneimittelreport (2019). https:\/\/www.barmer.de\/blob\/192556\/b7b2e41d474e012dd5fbfa087f0c0dfb\/data\/dl-report-komplett.pdf"},{"issue":"3","key":"1219_CR38","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.clinthera.2019.01.009","volume":"41","author":"S Ailawadhi","year":"2019","unstructured":"Ailawadhi, S., DerSarkissian, M., Duh, M.S., et al.: Cost offsets in the treatment journeys of patients with relapsed\/refractory multiple myeloma. Clin. Ther. 41(3), 477\u2013493 (2019)","journal-title":"Clin. Ther."},{"key":"1219_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2018.09.187","author":"E Walter","year":"2018","unstructured":"Walter, E., Lazic-Peric, A., Schalle, K., et al.: Economic analysis of costs and resource consumption of ixazomib in patients with relapsed\/refractory multiple myeloma in Austria. Value Health (2018). https:\/\/doi.org\/10.1016\/j.jval.2018.09.187","journal-title":"Value Health"},{"issue":"12","key":"1219_CR40","doi-asserted-by":"publisher","first-page":"1312","DOI":"10.1200\/JCO.2016.71.1663","volume":"35","author":"CHY van Beurden-Tan","year":"2017","unstructured":"van Beurden-Tan, C.H.Y., Franken, M.G., Blommestein, H.M., et al.: Systematic literature review and network meta-analysis of treatment outcomes in relapsed and\/or refractory multiple myeloma. J. Clin. Oncol. 35(12), 1312\u20131319 (2017)","journal-title":"J. Clin. Oncol."},{"key":"1219_CR41","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1080\/17474086.2016.1195254","volume":"9","author":"S Jagannath","year":"2016","unstructured":"Jagannath, S., Roy, A., Kish, J., et al.: Real-world treatment patterns and associated progression-free survival in relapsed\/refractory multiple myeloma among US community oncology practices. Expert Rev. Hematol. 9, 707\u2013717 (2016)","journal-title":"Expert Rev. Hematol."},{"key":"1219_CR42","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1080\/10428194.2016.1177772","volume":"58","author":"K Weisel","year":"2017","unstructured":"Weisel, K., Doyen, C., Dimopoulos, M., et al.: A systematic literature review and network meta-analysis of treatments for patients with untreated multiple myeloma not eligible for stem cell transplantation. Leuk. Lymphoma 58, 153\u2013161 (2017)","journal-title":"Leuk. Lymphoma"},{"key":"1219_CR43","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.clml.2017.12.012","volume":"18","author":"P Hari","year":"2018","unstructured":"Hari, P., Romanus, D., Palumbo, A., et al.: Prolonged duration of therapy is associated with improved survival in patients treated for relapsed\/refractory multiple myeloma in routine clinical care in the United States. Clin. Lymphoma Myeloma Leuk. 18, 152\u2013160 (2018)","journal-title":"Clin. Lymphoma Myeloma Leuk."}],"container-title":["The European Journal of Health Economics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-020-01219-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10198-020-01219-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10198-020-01219-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,10]],"date-time":"2021-07-10T23:41:58Z","timestamp":1625960518000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10198-020-01219-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,7,11]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1219"],"URL":"https:\/\/doi.org\/10.1007\/s10198-020-01219-3","relation":{},"ISSN":["1618-7598","1618-7601"],"issn-type":[{"type":"print","value":"1618-7598"},{"type":"electronic","value":"1618-7601"}],"subject":[],"published":{"date-parts":[[2020,7,11]]},"assertion":[{"value":"1 November 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}